Entering text into the input field will update the search result below

Verastem on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma; shares ahead 3%

Oct. 31, 2017 9:55 AM ETVerastem, Inc. (VSTM) StockBy: Douglas W. House, SA News Editor7 Comments
  • Based on FDA feedback, Verastem's (NASDAQ:VSTM +3.3%) New Drug Application (NDA) seeking approval for duvelisib will include requests for full approval for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and accelerated approval for relapsed/refractory follicular lymphoma (FL).
  • The company expects to submit the NDA in Q1 2018.
  • Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.
  • Previously: Verastem's duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket (Sept. 6)

Recommended For You

About VSTM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VSTM--
Verastem, Inc.